



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-845/S-004

INO Therapeutics, Inc.
Attention: Mary Ellen Zamstein
Senior Director, Regulatory Affairs
6 State Route 173
Clinton, NJ 08809

Dear Ms. Zamstein:

Please refer to your supplemental new drug application dated March 21, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for INOmax (nitric oxide) for Inhalation.

We acknowledge receipt of your submission dated October 30, 2007.

This supplemental new drug application provides for labeling revised as follows:

1. The Carcinogenesis, Mutagenesis, Impairment of Fertility section has been changed from:

Nitric oxide has demonstrated genotoxicity in Salmonella (Ames Test), human lymphocytes, and after *in vivo* exposure in rats. There are no animal or human studies to evaluate nitric oxide for effects on fertility or harm to the developing fetus.

To:

No evidence of a carcinogenic effect was apparent, at inhalation exposures up to the recommended dose (20 ppm), in rats for 20 hr/day for up to two years. Higher exposures have not been investigated.

Nitric oxide has demonstrated genotoxicity in Salmonella (Ames Test), human lymphocytes, and after *in vivo* exposure in rats. There are no animal or human studies to evaluate nitric oxide for effects on fertility.

2. The copyright date has been revised.

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on October 30, 2007.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Mr. Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
12/4/2007 04:42:28 PM